Psychiatrists' perceptions of medication adherence among patients with schizophrenia: An international survey

Shunya Kurokawa; Taishiro Kishimoto; Kuan Pin Su; Jane Pei Chen Chang; Hui Chih Chang; Xin Yu; Nuno Rodrigues-Silva; Jimmi Nielsen; Anish Unadkat; David Castle; Peter M. Haddad; Deyvis Rocha; Ary Gadelha; Styliani Kaliora; Georgios Petrides; Ofer Agid; Yuki Tazawa; Akihiro Takamiya; Toshiro Horigome; John M. Kane

doi:10.1016/j.schres.2019.07.028

Psychiatrists' perceptions of medication adherence among patients with schizophrenia: An international survey

Shunya Kurokawa, Taishiro Kishimoto, Kuan Pin Su, Jane Pei Chen Chang, Hui Chih Chang, Xin Yu, Nuno Rodrigues-Silva, Jimmi Nielsen, Anish Unadkat, David Castle, Peter M. Haddad, Deyvis Rocha, Ary Gadelha, Styliani Kaliora, Georgios Petrides, Ofer Agid, Yuki Tazawa, Akihiro Takamiya, Toshiro Horigome, John M. Kane

精神・神経科学

研究成果: Letter › 査読

1 被引用数 (Scopus)

本文言語	English
ページ（範囲）	105-107
ページ数	3
ジャーナル	Schizophrenia Research
巻	211
DOI	https://doi.org/10.1016/j.schres.2019.07.028
出版ステータス	Published - 2019 9月

ASJC Scopus subject areas

精神医学および精神衛生
生物学的精神医学

UN SDG

この成果は、次の持続可能な開発目標に貢献しています

文献へのアクセス

10.1016/j.schres.2019.07.028

他のファイルとリンク

引用スタイル

Kurokawa, S., Kishimoto, T., Su, K. P., Chang, J. P. C., Chang, H. C., Yu, X., Rodrigues-Silva, N., Nielsen, J., Unadkat, A., Castle, D., Haddad, P. M., Rocha, D., Gadelha, A., Kaliora, S., Petrides, G., Agid, O., Tazawa, Y., Takamiya, A., Horigome, T., & Kane, J. M. (2019). Psychiatrists' perceptions of medication adherence among patients with schizophrenia: An international survey. Schizophrenia Research, 211, 105-107. https://doi.org/10.1016/j.schres.2019.07.028

Kurokawa, S, Kishimoto, T, Su, KP, Chang, JPC, Chang, HC, Yu, X, Rodrigues-Silva, N, Nielsen, J, Unadkat, A, Castle, D, Haddad, PM, Rocha, D, Gadelha, A, Kaliora, S, Petrides, G, Agid, O, Tazawa, Y, Takamiya, A, Horigome, T & Kane, JM 2019, 'Psychiatrists' perceptions of medication adherence among patients with schizophrenia: An international survey', Schizophrenia Research, vol. 211, pp. 105-107. https://doi.org/10.1016/j.schres.2019.07.028

@article{db49b4f08e544e8a91184e5fe83acb97,

title = "Psychiatrists' perceptions of medication adherence among patients with schizophrenia: An international survey",

keywords = "Adherence, Antipsychotics, Long-acting injectable antipsychotics, Perception, Schizophrenia",

author = "Shunya Kurokawa and Taishiro Kishimoto and Su, {Kuan Pin} and Chang, {Jane Pei Chen} and Chang, {Hui Chih} and Xin Yu and Nuno Rodrigues-Silva and Jimmi Nielsen and Anish Unadkat and David Castle and Haddad, {Peter M.} and Deyvis Rocha and Ary Gadelha and Styliani Kaliora and Georgios Petrides and Ofer Agid and Yuki Tazawa and Akihiro Takamiya and Toshiro Horigome and Kane, {John M.}",

note = "Funding Information: Dr. Petrides has received research support by the National Institute of Mental Health (NIMH), National Institute of Aging (NIA), and St. Jude Medical . Funding Information: Dr. Kane has been a consultant to Alkermes, Janssen, Pfizer, Bristol-Myers Squibb, Dainippon Sumitomo/Sunovion, Johnson & Johnson, Otsuka, Pierre Fabre, Takeda, IntraCellular Therapies, Merck, Lundbeck, Neurocrine, Reviva, Roche,Teva, and he has received honoraria for lectures from Otsuka, Bristol-Myers Squibb, Janssen and Lundbeck. He is a shareholder LB Pharma and The Vanguard Research Group. He has received grant support from The Center for Medicare and Medicaid Innovation, National Institute of Mental Health , Otsuka , Lundbeck and Janssen . Funding Information: Dr. Kishimoto has received consultant fees from Otsuka, Pfizer, and Dainippon Sumitomo, and speaker's honoraria from Banyu, Eli Lilly, Dainippon Sumitomo, Janssen, Novartis, Otsuka, and Pfizer. He has received grant support from the Byoutaitaishakenkyukai Fellowship (Fellowship of Astellas Foundation of Research on Metabolic Disorders) and Eli Lilly Fellowship for Clinical Psychopharmacology.Drs. J. Chang, H. Chang, and Su are supported by the following grants: MOST 106-2314-B-039-027-MY3, 106-2314-B-038-049, 106-2314-B-039-031, 106-2314-B-039-035, and 105-2918-I-039-001 from the Ministry of Science and Technology, Taiwan; NHRI-EX106-10528NI from the National Health Research Institutes, Taiwan; and CMU106-S-33, CRS-106-063, DMR-107-202, DMR-107-204, DMR-107-091, DRM-107-097, DRM-108-091, CRS-108-048 and the Chinese Medicine Research Center from the China Medical University, Taiwan.Dr. Castle has received grant monies for research from Eli Lilly, Janssen Cilag, Roche, Allergen, Bristol-Myers Squibb, Pfizer, Lundbeck, Astra Zeneca, and Hospira. He has received travel support and honoraria for talks and consultancy from Eli Lilly, Bristol-Myers Squibb, Astra Zeneca, Lundbeck, Janssen Cilag, Pfizer, Organon, Sanofi-Aventis, Wyeth, Hospira, Servier, and Seqirus, and is a current Advisory Board Member for Lu AA21004: Lundbeck; Varenicline: Pfizer; Asenapine: Lundbeck; Aripiprazole LAI: Lundbeck; Lisdexamfetamine: Shire; Lurasidone: Servier; Brexpiprazole: Lundbeck; Treatment Resistant Depression: LivaNova. He is founder of the Optimal Health Program, currently operating as Optimal Wellness. He does not knowingly have stocks or shares in any pharmaceutical company.Dr. Petrides has received research support by the National Institute of Mental Health (NIMH), National Institute of Aging (NIA), and St. Jude Medical.Dr. Agid has received speaker's honoraria from Janssen-Ortho (Johnson & Johnson), Lundbeck, Otsuka, Mylan Pharmaceuticals, HLS, and Novartis, and consultant fees from Janssen-Ortho (Johnson & Johnson), Lundbeck, Otsuka, Sumitomo Dainippon Pharma, and Minerva. He has also received research support from Boehringer Ingelheim, Neurocrine Biosciences, Janssen-Ortho (Johnson & Johnson), Otsuka, Neurocrine Bioscience, Acadia, Syneurx, and diaMentis.Dr. Kane has been a consultant to Alkermes, Janssen, Pfizer, Bristol-Myers Squibb, Dainippon Sumitomo/Sunovion, Johnson & Johnson, Otsuka, Pierre Fabre, Takeda, IntraCellular Therapies, Merck, Lundbeck, Neurocrine, Reviva, Roche,Teva, and he has received honoraria for lectures from Otsuka, Bristol-Myers Squibb, Janssen and Lundbeck. He is a shareholder LB Pharma and The Vanguard Research Group. He has received grant support from The Center for Medicare and Medicaid Innovation, National Institute of Mental Health, Otsuka, Lundbeck and Janssen. The authors thank Stanley Ng for the data collection and entering. Funding Information: Dr. Kishimoto has received consultant fees from Otsuka, Pfizer, and Dainippon Sumitomo, and speaker's honoraria from Banyu, Eli Lilly, Dainippon Sumitomo, Janssen, Novartis, Otsuka, and Pfizer. He has received grant support from the Byoutaitaishakenkyukai Fellowship (Fellowship of Astellas Foundation of Research on Metabolic Disorders) and Eli Lilly Fellowship for Clinical Psychopharmacology. Funding Information: Drs. J. Chang, H. Chang, and Su are supported by the following grants: MOST 106-2314-B-039-027-MY3 , 106-2314-B-038-049 , 106-2314-B-039-031 , 106-2314-B-039-035 , and 105-2918-I-039-001 from the Ministry of Science and Technology, Taiwan ; NHRI-EX106-10528NI from the National Health Research Institutes , Taiwan; and CMU106-S-33 , CRS-106-063 , DMR-107-202 , DMR-107-204 , DMR-107-091 , DRM-107-097 , DRM-108-091 , CRS-108-048 and the Chinese Medicine Research Center from the China Medical University, Taiwan . ",

year = "2019",

month = sep,

doi = "10.1016/j.schres.2019.07.028",

language = "English",

volume = "211",

pages = "105--107",

journal = "Schizophrenia Research",

issn = "0920-9964",

publisher = "Elsevier",

}

TY - JOUR

T1 - Psychiatrists' perceptions of medication adherence among patients with schizophrenia

T2 - An international survey

AU - Kurokawa, Shunya

AU - Kishimoto, Taishiro

AU - Su, Kuan Pin

AU - Chang, Jane Pei Chen

AU - Chang, Hui Chih

AU - Yu, Xin

AU - Rodrigues-Silva, Nuno

AU - Nielsen, Jimmi

AU - Unadkat, Anish

AU - Castle, David

AU - Haddad, Peter M.

AU - Rocha, Deyvis

AU - Gadelha, Ary

AU - Kaliora, Styliani

AU - Petrides, Georgios

AU - Agid, Ofer

AU - Tazawa, Yuki

AU - Takamiya, Akihiro

AU - Horigome, Toshiro

AU - Kane, John M.

N1 - Funding Information: Dr. Petrides has received research support by the National Institute of Mental Health (NIMH), National Institute of Aging (NIA), and St. Jude Medical . Funding Information: Dr. Kane has been a consultant to Alkermes, Janssen, Pfizer, Bristol-Myers Squibb, Dainippon Sumitomo/Sunovion, Johnson & Johnson, Otsuka, Pierre Fabre, Takeda, IntraCellular Therapies, Merck, Lundbeck, Neurocrine, Reviva, Roche,Teva, and he has received honoraria for lectures from Otsuka, Bristol-Myers Squibb, Janssen and Lundbeck. He is a shareholder LB Pharma and The Vanguard Research Group. He has received grant support from The Center for Medicare and Medicaid Innovation, National Institute of Mental Health , Otsuka , Lundbeck and Janssen . Funding Information: Dr. Kishimoto has received consultant fees from Otsuka, Pfizer, and Dainippon Sumitomo, and speaker's honoraria from Banyu, Eli Lilly, Dainippon Sumitomo, Janssen, Novartis, Otsuka, and Pfizer. He has received grant support from the Byoutaitaishakenkyukai Fellowship (Fellowship of Astellas Foundation of Research on Metabolic Disorders) and Eli Lilly Fellowship for Clinical Psychopharmacology.Drs. J. Chang, H. Chang, and Su are supported by the following grants: MOST 106-2314-B-039-027-MY3, 106-2314-B-038-049, 106-2314-B-039-031, 106-2314-B-039-035, and 105-2918-I-039-001 from the Ministry of Science and Technology, Taiwan; NHRI-EX106-10528NI from the National Health Research Institutes, Taiwan; and CMU106-S-33, CRS-106-063, DMR-107-202, DMR-107-204, DMR-107-091, DRM-107-097, DRM-108-091, CRS-108-048 and the Chinese Medicine Research Center from the China Medical University, Taiwan.Dr. Castle has received grant monies for research from Eli Lilly, Janssen Cilag, Roche, Allergen, Bristol-Myers Squibb, Pfizer, Lundbeck, Astra Zeneca, and Hospira. He has received travel support and honoraria for talks and consultancy from Eli Lilly, Bristol-Myers Squibb, Astra Zeneca, Lundbeck, Janssen Cilag, Pfizer, Organon, Sanofi-Aventis, Wyeth, Hospira, Servier, and Seqirus, and is a current Advisory Board Member for Lu AA21004: Lundbeck; Varenicline: Pfizer; Asenapine: Lundbeck; Aripiprazole LAI: Lundbeck; Lisdexamfetamine: Shire; Lurasidone: Servier; Brexpiprazole: Lundbeck; Treatment Resistant Depression: LivaNova. He is founder of the Optimal Health Program, currently operating as Optimal Wellness. He does not knowingly have stocks or shares in any pharmaceutical company.Dr. Petrides has received research support by the National Institute of Mental Health (NIMH), National Institute of Aging (NIA), and St. Jude Medical.Dr. Agid has received speaker's honoraria from Janssen-Ortho (Johnson & Johnson), Lundbeck, Otsuka, Mylan Pharmaceuticals, HLS, and Novartis, and consultant fees from Janssen-Ortho (Johnson & Johnson), Lundbeck, Otsuka, Sumitomo Dainippon Pharma, and Minerva. He has also received research support from Boehringer Ingelheim, Neurocrine Biosciences, Janssen-Ortho (Johnson & Johnson), Otsuka, Neurocrine Bioscience, Acadia, Syneurx, and diaMentis.Dr. Kane has been a consultant to Alkermes, Janssen, Pfizer, Bristol-Myers Squibb, Dainippon Sumitomo/Sunovion, Johnson & Johnson, Otsuka, Pierre Fabre, Takeda, IntraCellular Therapies, Merck, Lundbeck, Neurocrine, Reviva, Roche,Teva, and he has received honoraria for lectures from Otsuka, Bristol-Myers Squibb, Janssen and Lundbeck. He is a shareholder LB Pharma and The Vanguard Research Group. He has received grant support from The Center for Medicare and Medicaid Innovation, National Institute of Mental Health, Otsuka, Lundbeck and Janssen. The authors thank Stanley Ng for the data collection and entering. Funding Information: Dr. Kishimoto has received consultant fees from Otsuka, Pfizer, and Dainippon Sumitomo, and speaker's honoraria from Banyu, Eli Lilly, Dainippon Sumitomo, Janssen, Novartis, Otsuka, and Pfizer. He has received grant support from the Byoutaitaishakenkyukai Fellowship (Fellowship of Astellas Foundation of Research on Metabolic Disorders) and Eli Lilly Fellowship for Clinical Psychopharmacology. Funding Information: Drs. J. Chang, H. Chang, and Su are supported by the following grants: MOST 106-2314-B-039-027-MY3 , 106-2314-B-038-049 , 106-2314-B-039-031 , 106-2314-B-039-035 , and 105-2918-I-039-001 from the Ministry of Science and Technology, Taiwan ; NHRI-EX106-10528NI from the National Health Research Institutes , Taiwan; and CMU106-S-33 , CRS-106-063 , DMR-107-202 , DMR-107-204 , DMR-107-091 , DRM-107-097 , DRM-108-091 , CRS-108-048 and the Chinese Medicine Research Center from the China Medical University, Taiwan .

PY - 2019/9

Y1 - 2019/9

KW - Adherence

KW - Antipsychotics

KW - Long-acting injectable antipsychotics

KW - Perception

KW - Schizophrenia

UR - http://www.scopus.com/inward/record.url?scp=85071391495&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85071391495&partnerID=8YFLogxK

U2 - 10.1016/j.schres.2019.07.028

DO - 10.1016/j.schres.2019.07.028

M3 - Letter

C2 - 31371039

AN - SCOPUS:85071391495

SN - 0920-9964

VL - 211

SP - 105

EP - 107

JO - Schizophrenia Research

JF - Schizophrenia Research

ER -